Evaluation of familial mediterranean fever patients: a single center experience

Introduction Familial Mediterranean Fever (FMF) is an autosomal recessive autoinflammatory disease due to mutations in MEFV, and characterized by recurrent acute attacks of fever and serosal inflamation. The disease mainly affects populations from the Mediterranean basin, especially Arabs, Turks, Jews, and Armenians. The diagnosis of the disease relies on clinical criteria, family history, and ethnic considerations, and genetic analysis of known mutations. Standart therapy for the prevention of acute attacks and also disease-related amiloidosis is colchicine. Valid therapeutic alternatives are anti-IL-1 agents in unresponder or noncompliant patients.